Life Sciences

AndroGel manufacturers accussed of delaying generics

Pharma Compliance Alert, April 22, 2009

Unimed Pharmaceuticals, Solvay Pharmaceuticals, Watson Pharmaceuticals, Par Pharmaceuticals, and Paddock Laboratories are facing allegations they conspired to keep generic versions of AndroGel off the market.

A lawsuit filed in New Jersey federal court claims the companies violated the Anti-Trust Act by agreeing to delay the release of generic versions of the testosterone replacement therapy. As a result, purchasers of the drug were overcharged millions of dollars, the suit claims.

The Federal Trade Commission filed a similar suit against Solvay, Watson, and Par in February.